BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 9, 2006--Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that is has entered into a collaborative agreement with Harvard Medical School (HMS) and the Harvard Institute of Proteomics, a division of HMS. Under the terms of the agreement, Lumera and HMS will develop a next generation silicon chip substrate that combines Lumera’s NanoCapture(TM) technology with HMS’s NAPPA(TM) methodology (nucleic acid programmable protein arrays). The resultant 10,000-spot very high density protein arrays are expected to significantly increase the speed of drug discovery and life science research.